These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies. Aashiq M; Silverman DA; Na'ara S; Takahashi H; Amit M Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31533238 [TBL] [Abstract][Full Text] [Related]
43. Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. Dunn LA; Sherman EJ; Baxi SS; Tchekmedyian V; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Ni A; Li D; Knauf JA; Pfister DG; Fagin JA; Ho AL J Clin Endocrinol Metab; 2019 May; 104(5):1417-1428. PubMed ID: 30256977 [TBL] [Abstract][Full Text] [Related]
44. Combination Treatment with the BRAF Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573 [TBL] [Abstract][Full Text] [Related]
45. Seven-year follow-up of a juvenile female with papillary thyroid carcinoma with poor outcome, BRAF mutation and loss of expression of iodine-metabolizing genes. Oler G; Nakabashi CD; Biscolla RP; Cerutti JM Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1313-6. PubMed ID: 19169486 [TBL] [Abstract][Full Text] [Related]
46. BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. Durante C; Tallini G; Puxeddu E; Sponziello M; Moretti S; Ligorio C; Cavaliere A; Rhoden KJ; Verrienti A; Maranghi M; Giacomelli L; Russo D; Filetti S Eur J Endocrinol; 2011 Sep; 165(3):455-63. PubMed ID: 21653734 [TBL] [Abstract][Full Text] [Related]
47. ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compared to that of corresponding normal thyroid tissues. Kim SW; Kim HK; Lee JI; Jang HW; Choe JH; Kim JH; Kim JS; Hur KY; Kim JH; Chung JH Endocr Res; 2013; 38(2):89-97. PubMed ID: 23544999 [TBL] [Abstract][Full Text] [Related]
48. Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting. Hilhorst R; van den Berg A; Boender P; van Wezel T; Kievits T; de Wijn R; Ruijtenbeek R; Corver WE; Morreau H Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760447 [TBL] [Abstract][Full Text] [Related]
49. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E. Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530 [TBL] [Abstract][Full Text] [Related]
50. Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis. Prete A; Lo AS; Sadow PM; Bhasin SS; Antonello ZA; Vodopivec DM; Ullas S; Sims JN; Clohessy J; Dvorak AM; Sciuto T; Bhasin M; Murphy-Ullrich JE; Lawler J; Karumanchi SA; Nucera C Clin Cancer Res; 2018 Dec; 24(23):6078-6097. PubMed ID: 30076136 [TBL] [Abstract][Full Text] [Related]
52. Role of BRAF in thyroid oncogenesis. Caronia LM; Phay JE; Shah MH Clin Cancer Res; 2011 Dec; 17(24):7511-7. PubMed ID: 21900390 [TBL] [Abstract][Full Text] [Related]
53. POU5F1B is responsible for the acquired resistance to dabrafenib in papillary thyroid cancer cells with the BRAF V600E mutation. Li J; Yu Y Endocrine; 2024 Aug; ():. PubMed ID: 39136897 [TBL] [Abstract][Full Text] [Related]
54. Epigenetic Modifications in Thyroid Cancer Cells Restore NIS and Radio-Iodine Uptake and Promote Cell Death. Wächter S; Damanakis AI; Elxnat M; Roth S; Wunderlich A; Verburg FA; Fellinger SA; Bartsch DK; Di Fazio P J Clin Med; 2018 Mar; 7(4):. PubMed ID: 29561759 [TBL] [Abstract][Full Text] [Related]
56. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212 [TBL] [Abstract][Full Text] [Related]
57. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma. Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737 [TBL] [Abstract][Full Text] [Related]
58. Increased CYP24A1 expression is associated with BRAF(V600E) mutation and advanced stages in papillary thyroid carcinoma. Zou M; BinHumaid FS; Alzahrani AS; Baitei EY; Al-Mohanna FA; Meyer BF; Shi Y Clin Endocrinol (Oxf); 2014 Jul; 81(1):109-16. PubMed ID: 24382015 [TBL] [Abstract][Full Text] [Related]
59. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas. Yoon M; Jung SJ; Kim TH; Ha TK; Urm SH; Park JS; Lee SM; Bae SK Endocr Res; 2016; 41(1):64-9. PubMed ID: 26513490 [TBL] [Abstract][Full Text] [Related]
60. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition. Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]